Tapinarof

Aryl Hydrocarbon Receptor Agonist — DERMATOLOGICALS

Key facts

Tapinarof is an onp drug in the Aryl Hydrocarbon Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2022. Its mechanism of action is classified as Aryl Hydrocarbon Receptor Agonists. DrugCentral lists 1 molecular target, including AHR. Recorded indications include Plaque psoriasis.

• Approval status: onp (first approved 2022 by the FDA).
• Drug class: Aryl Hydrocarbon Receptor Agonist.
• Mechanism of action: Aryl Hydrocarbon Receptor Agonists.
• Molecular targets: AHR (1 listed in DrugCentral).
• Indications: Plaque psoriasis.
• ATC code: D05AX07 (Other antipsoriatics for topical use).
• Molecular formula: C17H18O2; molecular weight 254.33 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Plaque psoriasis

Mechanism & targets

• Mechanism of action (MoA): Aryl Hydrocarbon Receptor Agonists
• Established pharmacologic class: Aryl Hydrocarbon Receptor Agonist

Molecular targets (1)

Target	Gene	Action	Activity
Aryl hydrocarbon receptor	AHR	agonist	EC50 9.80

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2022-05-23	FDA	—	DERMAVANT SCIENCES INC

ATC classification

ATC code	Therapeutic hierarchy
D05AX07	DERMATOLOGICALS › ANTIPSORIATICS › ANTIPSORIATICS FOR TOPICAL USE › Other antipsoriatics for topical use

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Folliculitis	853.2
Dermatitis contact	624.8
Application site folliculitis	382.3
Skin burning sensation	223.5
Application site erythema	134.7
Application site pain	125.0
Milia	116.5
Headache	116.2
Erythema	108.5
Pain of skin	92.8
Pruritus	87.1
Acne	81.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Tapinarof is on its molecule page.

• Molecular formula: C₁₇H₁₈O₂
• Molecular weight: 254.33 g/mol
• CAS number: —
• InChIKey: ZISJNXNHJRQYJO-CMDGGOBGSA-N
• PubChem CID: 6439522

CC(C)C1=C(O)C=C(\C=C\C2=CC=CC=C2)C=C1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tapinarof used for?

DrugCentral lists the following indications for Tapinarof: Plaque psoriasis.

How does Tapinarof work?

Tapinarof is classified as Aryl Hydrocarbon Receptor Agonists; its molecular targets in DrugCentral include AHR (agonist).

When was Tapinarof first approved?

Tapinarof was first approved by the FDA in 2022.

What drug class does Tapinarof belong to?

Tapinarof is in the Aryl Hydrocarbon Receptor Agonist class.

What is the chemical formula of Tapinarof?

Tapinarof has the molecular formula C17H18O2 and a molecular weight of 254.33 g/mol.

Sources

• DrugCentral drug card 5521 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL259571 — compound record and bioactivity
• PubChem CID 6439522 — chemical identifiers
• DrugBank DB06083 — drug record
• FDA UNII 84HW7D0V04 — substance identity
• DailyMed: FDA labels for Tapinarof — current prescribing information (label search)
• UniProt P35869 (AHR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.